• Vertical Integration
    RA Chem Pharma Limited is a vertically integrated pharmaceutical
    company Over the past 10 years, it has expanded its spectrum by
    establishing state-of-the-art manufacturing facilities in API
    Read more
  • API
    API division produces under cGMP conditions Active ingredients
    and Drug intermediates both for own marketing and custom manufacturing.
    The unit is located about 220 km from Hyderabad enroute to Vijayawada
    at Jaggaiahpet, Krishna District.
    Readmore...
  • Formulations
    Formulations division is engaged in the manufacture of Finished
    Dosage Forms at its plant located at Nacharam, Hyderabad.
    Read more
  • CRBio
    State of the art, centrally located Clinical Research facility tailored to
    meet the constantly evolving needs of formulators
    Read more

welcome to Ra Chem Pharma Ltd

RA Chem Pharma Limited is a vertically integrated pharmaceutical company.Over the past 10 years, it has expanded its spectrum

by establishing state-of-the-art manufacturing facilities in API, Formulations and Clinical Research.

Facilities

  • API Trailblazing synthesis of niche molecules & custom manufacturing. Read more
  • Formulations Distinctive entity with meticulous emphasis on solid-dosage forms Read more
  • CRBio State of the art, centrally located Clinical Research facility tailored to meet Read more
  • Vertical Integration Seamless homogenization of three divisions to empower RA as one. Read more

DEDICATED FACILITIES


  • API MANUFACTURING AT JAGGAIAHPET

    Custom built API manufacturing site equipped with the latest technology, with a capacity of 210 KL and 7 clean rooms. The facility is inspected and approved by the Drug Control Administration of AP, USFDA, KFDA, PMDA, KFDA and WHO GMP



  • FINISHED DOSAGE FORMS MANUFACTURING AT NACHARAM

    Expansive manufacturing unit spread across 5000 m2 exclusively for solid dosage forms, with special emphasis on modified-release formulations. The facility is inspected and approved by USFDA and MoH – Iran.



  • CLINICAL RESEARCH AND BIOSCIENCES AT BALANAGAR

    State-of-the-art, modern facility containing 114 beds and 5 LC-MS/MS and approved by major regulatory authorities including USFDA, EU (Project based), MoH – Turkey, BPFK – Malaysia and UAE MoH.



  • API MANUFACTURING AT JAGGAIAHPET

    Custom built API manufacturing site equipped with the latest technology, with a capacity of 210 KL and 7 clean rooms. The facility is inspected and approved by the Drug Control Administration of AP, USFDA, KFDA, PMDA, KFDA and WHO GMP



  • FINISHED DOSAGE FORMS MANUFACTURING AT NACHARAM

    Expansive manufacturing unit spread across 5000 m2 exclusively for solid dosage forms, with special emphasis on modified-release formulations. The facility is inspected and approved by USFDA and MoH – Iran.



  • CLINICAL RESEARCH AND BIOSCIENCES AT BALANAGAR

    State-of-the-art, modern facility containing 114 beds and 5 LC-MS/MS and approved by major regulatory authorities including USFDA, EU (Project based), MoH – Turkey, BPFK – Malaysia and UAE MoH.



  • API MANUFACTURING AT JAGGAIAHPET

    Custom built API manufacturing site equipped with the latest technology, with a capacity of 210 KL and 7 clean rooms. The facility is inspected and approved by the Drug Control Administration of AP, USFDA, KFDA, PMDA, KFDA and WHO GMP



  • FINISHED DOSAGE FORMS MANUFACTURING AT NACHARAM

    Expansive manufacturing unit spread across 5000 m2 exclusively for solid dosage forms, with special emphasis on modified-release formulations. The facility is inspected and approved by USFDA and MoH – Iran.



  • CLINICAL RESEARCH AND BIOSCIENCES AT BALANAGAR

    State-of-the-art, modern facility containing 114 beds and 5 LC-MS/MS and approved by major regulatory authorities including USFDA, EU (Project based), MoH – Turkey, BPFK – Malaysia and UAE MoH.



  • API MANUFACTURING AT JAGGAIAHPET

    Custom built API manufacturing site equipped with the latest technology, with a capacity of 210 KL and 7 clean rooms. The facility is inspected and approved by the Drug Control Administration of AP, USFDA, KFDA, PMDA, KFDA and WHO GMP



  • FINISHED DOSAGE FORMS MANUFACTURING AT NACHARAM

    Expansive manufacturing unit spread across 5000 m2 exclusively for solid dosage forms, with special emphasis on modified-release formulations. The facility is inspected and approved by USFDA and MoH – Iran.



  • CLINICAL RESEARCH AND BIOSCIENCES AT BALANAGAR

    State-of-the-art, modern facility containing 114 beds and 5 LC-MS/MS and approved by major regulatory authorities including USFDA, EU (Project based), MoH – Turkey, BPFK – Malaysia and UAE MoH.



  • API MANUFACTURING AT JAGGAIAHPET

    Custom built API manufacturing site equipped with the latest technology, with a capacity of 210 KL and 7 clean rooms. The facility is inspected and approved by the Drug Control Administration of AP, USFDA, KFDA, PMDA, KFDA and WHO GMP



  • FINISHED DOSAGE FORMS MANUFACTURING AT NACHARAM

    Expansive manufacturing unit spread across 5000 m2 exclusively for solid dosage forms, with special emphasis on modified-release formulations. The facility is inspected and approved by USFDA and MoH – Iran.



  • CLINICAL RESEARCH AND BIOSCIENCES AT BALANAGAR

    State-of-the-art, modern facility containing 114 beds and 5 LC-MS/MS and approved by major regulatory authorities including USFDA, EU (Project based), MoH – Turkey, BPFK – Malaysia and UAE MoH.



  • API MANUFACTURING AT JAGGAIAHPET

    Custom built API manufacturing site equipped with the latest technology, with a capacity of 210 KL and 7 clean rooms. The facility is inspected and approved by the Drug Control Administration of AP, USFDA, KFDA, PMDA, KFDA and WHO GMP



  • FINISHED DOSAGE FORMS MANUFACTURING AT NACHARAM

    Expansive manufacturing unit spread across 5000 m2 exclusively for solid dosage forms, with special emphasis on modified-release formulations. The facility is inspected and approved by USFDA and MoH – Iran.



  • CLINICAL RESEARCH AND BIOSCIENCES AT BALANAGAR

    State-of-the-art, modern facility containing 114 beds and 5 LC-MS/MS and approved by major regulatory authorities including USFDA, EU (Project based), MoH – Turkey, BPFK – Malaysia and UAE MoH.



  • API MANUFACTURING AT JAGGAIAHPET

    Custom built API manufacturing site equipped with the latest technology, with a capacity of 210 KL and 7 clean rooms. The facility is inspected and approved by the Drug Control Administration of AP, USFDA, KFDA, PMDA, KFDA and WHO GMP



  • FINISHED DOSAGE FORMS MANUFACTURING AT NACHARAM

    Expansive manufacturing unit spread across 5000 m2 exclusively for solid dosage forms, with special emphasis on modified-release formulations. The facility is inspected and approved by USFDA and MoH – Iran.



  • CLINICAL RESEARCH AND BIOSCIENCES AT BALANAGAR

    State-of-the-art, modern facility containing 114 beds and 5 LC-MS/MS and approved by major regulatory authorities including USFDA, EU (Project based), MoH – Turkey, BPFK – Malaysia and UAE MoH.



  • API MANUFACTURING AT JAGGAIAHPET

    Custom built API manufacturing site equipped with the latest technology, with a capacity of 210 KL and 7 clean rooms. The facility is inspected and approved by the Drug Control Administration of AP, USFDA, KFDA, PMDA, KFDA and WHO GMP



  • FINISHED DOSAGE FORMS MANUFACTURING AT NACHARAM

    Expansive manufacturing unit spread across 5000 m2 exclusively for solid dosage forms, with special emphasis on modified-release formulations. The facility is inspected and approved by USFDA and MoH – Iran.



  • CLINICAL RESEARCH AND BIOSCIENCES AT BALANAGAR

    State-of-the-art, modern facility containing 114 beds and 5 LC-MS/MS and approved by major regulatory authorities including USFDA, EU (Project based), MoH – Turkey, BPFK – Malaysia and UAE MoH.



  • API MANUFACTURING AT JAGGAIAHPET

    Custom built API manufacturing site equipped with the latest technology, with a capacity of 210 KL and 7 clean rooms. The facility is inspected and approved by the Drug Control Administration of AP, USFDA, KFDA, PMDA, KFDA and WHO GMP



  • FINISHED DOSAGE FORMS MANUFACTURING AT NACHARAM

    Expansive manufacturing unit spread across 5000 m2 exclusively for solid dosage forms, with special emphasis on modified-release formulations. The facility is inspected and approved by USFDA and MoH – Iran.



  • CLINICAL RESEARCH AND BIOSCIENCES AT BALANAGAR

    State-of-the-art, modern facility containing 114 beds and 5 LC-MS/MS and approved by major regulatory authorities including USFDA, EU (Project based), MoH – Turkey, BPFK – Malaysia and UAE MoH.



  • API MANUFACTURING AT JAGGAIAHPET

    Custom built API manufacturing site equipped with the latest technology, with a capacity of 210 KL and 7 clean rooms. The facility is inspected and approved by the Drug Control Administration of AP, USFDA, KFDA, PMDA, KFDA and WHO GMP



  • FINISHED DOSAGE FORMS MANUFACTURING AT NACHARAM

    Expansive manufacturing unit spread across 5000 m2 exclusively for solid dosage forms, with special emphasis on modified-release formulations. The facility is inspected and approved by USFDA and MoH – Iran.



  • CLINICAL RESEARCH AND BIOSCIENCES AT BALANAGAR

    State-of-the-art, modern facility containing 114 beds and 5 LC-MS/MS and approved by major regulatory authorities including USFDA, EU (Project based), MoH – Turkey, BPFK – Malaysia and UAE MoH.



  • API MANUFACTURING AT JAGGAIAHPET

    Custom built API manufacturing site equipped with the latest technology, with a capacity of 210 KL and 7 clean rooms. The facility is inspected and approved by the Drug Control Administration of AP, USFDA, KFDA, PMDA, KFDA and WHO GMP



  • FINISHED DOSAGE FORMS MANUFACTURING AT NACHARAM

    Expansive manufacturing unit spread across 5000 m2 exclusively for solid dosage forms, with special emphasis on modified-release formulations. The facility is inspected and approved by USFDA and MoH – Iran.



  • CLINICAL RESEARCH AND BIOSCIENCES AT BALANAGAR

    State-of-the-art, modern facility containing 114 beds and 5 LC-MS/MS and approved by major regulatory authorities including USFDA, EU (Project based), MoH – Turkey, BPFK – Malaysia and UAE MoH.



  • API MANUFACTURING AT JAGGAIAHPET

    Custom built API manufacturing site equipped with the latest technology, with a capacity of 210 KL and 7 clean rooms. The facility is inspected and approved by the Drug Control Administration of AP, USFDA, KFDA, PMDA, KFDA and WHO GMP



  • FINISHED DOSAGE FORMS MANUFACTURING AT NACHARAM

    Expansive manufacturing unit spread across 5000 m2 exclusively for solid dosage forms, with special emphasis on modified-release formulations. The facility is inspected and approved by USFDA and MoH – Iran.



  • CLINICAL RESEARCH AND BIOSCIENCES AT BALANAGAR

    State-of-the-art, modern facility containing 114 beds and 5 LC-MS/MS and approved by major regulatory authorities including USFDA, EU (Project based), MoH – Turkey, BPFK – Malaysia and UAE MoH.



  • API MANUFACTURING AT JAGGAIAHPET

    Custom built API manufacturing site equipped with the latest technology, with a capacity of 210 KL and 7 clean rooms. The facility is inspected and approved by the Drug Control Administration of AP, USFDA, KFDA, PMDA, KFDA and WHO GMP



  • FINISHED DOSAGE FORMS MANUFACTURING AT NACHARAM

    Expansive manufacturing unit spread across 5000 m2 exclusively for solid dosage forms, with special emphasis on modified-release formulations. The facility is inspected and approved by USFDA and MoH – Iran.



  • CLINICAL RESEARCH AND BIOSCIENCES AT BALANAGAR

    State-of-the-art, modern facility containing 114 beds and 5 LC-MS/MS and approved by major regulatory authorities including USFDA, EU (Project based), MoH – Turkey, BPFK – Malaysia and UAE MoH.



  • API MANUFACTURING AT JAGGAIAHPET

    Custom built API manufacturing site equipped with the latest technology, with a capacity of 210 KL and 7 clean rooms. The facility is inspected and approved by the Drug Control Administration of AP, USFDA, KFDA, PMDA, KFDA and WHO GMP



  • FINISHED DOSAGE FORMS MANUFACTURING AT NACHARAM

    Expansive manufacturing unit spread across 5000 m2 exclusively for solid dosage forms, with special emphasis on modified-release formulations. The facility is inspected and approved by USFDA and MoH – Iran.



  • CLINICAL RESEARCH AND BIOSCIENCES AT BALANAGAR

    State-of-the-art, modern facility containing 114 beds and 5 LC-MS/MS and approved by major regulatory authorities including USFDA, EU (Project based), MoH – Turkey, BPFK – Malaysia and UAE MoH.



  • API MANUFACTURING AT JAGGAIAHPET

    Custom built API manufacturing site equipped with the latest technology, with a capacity of 210 KL and 7 clean rooms. The facility is inspected and approved by the Drug Control Administration of AP, USFDA, KFDA, PMDA, KFDA and WHO GMP



  • FINISHED DOSAGE FORMS MANUFACTURING AT NACHARAM

    Expansive manufacturing unit spread across 5000 m2 exclusively for solid dosage forms, with special emphasis on modified-release formulations. The facility is inspected and approved by USFDA and MoH – Iran.



  • CLINICAL RESEARCH AND BIOSCIENCES AT BALANAGAR

    State-of-the-art, modern facility containing 114 beds and 5 LC-MS/MS and approved by major regulatory authorities including USFDA, EU (Project based), MoH – Turkey, BPFK – Malaysia and UAE MoH.



  • API MANUFACTURING AT JAGGAIAHPET

    Custom built API manufacturing site equipped with the latest technology, with a capacity of 210 KL and 7 clean rooms. The facility is inspected and approved by the Drug Control Administration of AP, USFDA, KFDA, PMDA, KFDA and WHO GMP



  • FINISHED DOSAGE FORMS MANUFACTURING AT NACHARAM

    Expansive manufacturing unit spread across 5000 m2 exclusively for solid dosage forms, with special emphasis on modified-release formulations. The facility is inspected and approved by USFDA and MoH – Iran.



  • CLINICAL RESEARCH AND BIOSCIENCES AT BALANAGAR

    State-of-the-art, modern facility containing 114 beds and 5 LC-MS/MS and approved by major regulatory authorities including USFDA, EU (Project based), MoH – Turkey, BPFK – Malaysia and UAE MoH.



  • API MANUFACTURING AT JAGGAIAHPET

    Custom built API manufacturing site equipped with the latest technology, with a capacity of 210 KL and 7 clean rooms. The facility is inspected and approved by the Drug Control Administration of AP, USFDA, KFDA, PMDA, KFDA and WHO GMP



  • FINISHED DOSAGE FORMS MANUFACTURING AT NACHARAM

    Expansive manufacturing unit spread across 5000 m2 exclusively for solid dosage forms, with special emphasis on modified-release formulations. The facility is inspected and approved by USFDA and MoH – Iran.



  • CLINICAL RESEARCH AND BIOSCIENCES AT BALANAGAR

    State-of-the-art, modern facility containing 114 beds and 5 LC-MS/MS and approved by major regulatory authorities including USFDA, EU (Project based), MoH – Turkey, BPFK – Malaysia and UAE MoH.



  • API MANUFACTURING AT JAGGAIAHPET

    Custom built API manufacturing site equipped with the latest technology, with a capacity of 210 KL and 7 clean rooms. The facility is inspected and approved by the Drug Control Administration of AP, USFDA, KFDA, PMDA, KFDA and WHO GMP



  • FINISHED DOSAGE FORMS MANUFACTURING AT NACHARAM

    Expansive manufacturing unit spread across 5000 m2 exclusively for solid dosage forms, with special emphasis on modified-release formulations. The facility is inspected and approved by USFDA and MoH – Iran.



  • CLINICAL RESEARCH AND BIOSCIENCES AT BALANAGAR

    State-of-the-art, modern facility containing 114 beds and 5 LC-MS/MS and approved by major regulatory authorities including USFDA, EU (Project based), MoH – Turkey, BPFK – Malaysia and UAE MoH.



  • API MANUFACTURING AT JAGGAIAHPET

    Custom built API manufacturing site equipped with the latest technology, with a capacity of 210 KL and 7 clean rooms. The facility is inspected and approved by the Drug Control Administration of AP, USFDA, KFDA, PMDA, KFDA and WHO GMP



  • FINISHED DOSAGE FORMS MANUFACTURING AT NACHARAM

    Expansive manufacturing unit spread across 5000 m2 exclusively for solid dosage forms, with special emphasis on modified-release formulations. The facility is inspected and approved by USFDA and MoH – Iran.



  • CLINICAL RESEARCH AND BIOSCIENCES AT BALANAGAR

    State-of-the-art, modern facility containing 114 beds and 5 LC-MS/MS and approved by major regulatory authorities including USFDA, EU (Project based), MoH – Turkey, BPFK – Malaysia and UAE MoH.



  • API MANUFACTURING AT JAGGAIAHPET

    Custom built API manufacturing site equipped with the latest technology, with a capacity of 210 KL and 7 clean rooms. The facility is inspected and approved by the Drug Control Administration of AP, USFDA, KFDA, PMDA, KFDA and WHO GMP



  • FINISHED DOSAGE FORMS MANUFACTURING AT NACHARAM

    Expansive manufacturing unit spread across 5000 m2 exclusively for solid dosage forms, with special emphasis on modified-release formulations. The facility is inspected and approved by USFDA and MoH – Iran.



  • CLINICAL RESEARCH AND BIOSCIENCES AT BALANAGAR

    State-of-the-art, modern facility containing 114 beds and 5 LC-MS/MS and approved by major regulatory authorities including USFDA, EU (Project based), MoH – Turkey, BPFK – Malaysia and UAE MoH.



  • API MANUFACTURING AT JAGGAIAHPET

    Custom built API manufacturing site equipped with the latest technology, with a capacity of 210 KL and 7 clean rooms. The facility is inspected and approved by the Drug Control Administration of AP, USFDA, KFDA, PMDA, KFDA and WHO GMP



  • FINISHED DOSAGE FORMS MANUFACTURING AT NACHARAM

    Expansive manufacturing unit spread across 5000 m2 exclusively for solid dosage forms, with special emphasis on modified-release formulations. The facility is inspected and approved by USFDA and MoH – Iran.



  • CLINICAL RESEARCH AND BIOSCIENCES AT BALANAGAR

    State-of-the-art, modern facility containing 114 beds and 5 LC-MS/MS and approved by major regulatory authorities including USFDA, EU (Project based), MoH – Turkey, BPFK – Malaysia and UAE MoH.



  • API MANUFACTURING AT JAGGAIAHPET

    Custom built API manufacturing site equipped with the latest technology, with a capacity of 210 KL and 7 clean rooms. The facility is inspected and approved by the Drug Control Administration of AP, USFDA, KFDA, PMDA, KFDA and WHO GMP



  • FINISHED DOSAGE FORMS MANUFACTURING AT NACHARAM

    Expansive manufacturing unit spread across 5000 m2 exclusively for solid dosage forms, with special emphasis on modified-release formulations. The facility is inspected and approved by USFDA and MoH – Iran.



  • CLINICAL RESEARCH AND BIOSCIENCES AT BALANAGAR

    State-of-the-art, modern facility containing 114 beds and 5 LC-MS/MS and approved by major regulatory authorities including USFDA, EU (Project based), MoH – Turkey, BPFK – Malaysia and UAE MoH.



  • API MANUFACTURING AT JAGGAIAHPET

    Custom built API manufacturing site equipped with the latest technology, with a capacity of 210 KL and 7 clean rooms. The facility is inspected and approved by the Drug Control Administration of AP, USFDA, KFDA, PMDA, KFDA and WHO GMP



  • FINISHED DOSAGE FORMS MANUFACTURING AT NACHARAM

    Expansive manufacturing unit spread across 5000 m2 exclusively for solid dosage forms, with special emphasis on modified-release formulations. The facility is inspected and approved by USFDA and MoH – Iran.



  • CLINICAL RESEARCH AND BIOSCIENCES AT BALANAGAR

    State-of-the-art, modern facility containing 114 beds and 5 LC-MS/MS and approved by major regulatory authorities including USFDA, EU (Project based), MoH – Turkey, BPFK – Malaysia and UAE MoH.



  • API MANUFACTURING AT JAGGAIAHPET

    Custom built API manufacturing site equipped with the latest technology, with a capacity of 210 KL and 7 clean rooms. The facility is inspected and approved by the Drug Control Administration of AP, USFDA, KFDA, PMDA, KFDA and WHO GMP



  • FINISHED DOSAGE FORMS MANUFACTURING AT NACHARAM

    Expansive manufacturing unit spread across 5000 m2 exclusively for solid dosage forms, with special emphasis on modified-release formulations. The facility is inspected and approved by USFDA and MoH – Iran.



  • CLINICAL RESEARCH AND BIOSCIENCES AT BALANAGAR

    State-of-the-art, modern facility containing 114 beds and 5 LC-MS/MS and approved by major regulatory authorities including USFDA, EU (Project based), MoH – Turkey, BPFK – Malaysia and UAE MoH.



  • API MANUFACTURING AT JAGGAIAHPET

    Custom built API manufacturing site equipped with the latest technology, with a capacity of 210 KL and 7 clean rooms. The facility is inspected and approved by the Drug Control Administration of AP, USFDA, KFDA, PMDA, KFDA and WHO GMP



  • FINISHED DOSAGE FORMS MANUFACTURING AT NACHARAM

    Expansive manufacturing unit spread across 5000 m2 exclusively for solid dosage forms, with special emphasis on modified-release formulations. The facility is inspected and approved by USFDA and MoH – Iran.



  • CLINICAL RESEARCH AND BIOSCIENCES AT BALANAGAR

    State-of-the-art, modern facility containing 114 beds and 5 LC-MS/MS and approved by major regulatory authorities including USFDA, EU (Project based), MoH – Turkey, BPFK – Malaysia and UAE MoH.



  • API MANUFACTURING AT JAGGAIAHPET

    Custom built API manufacturing site equipped with the latest technology, with a capacity of 210 KL and 7 clean rooms. The facility is inspected and approved by the Drug Control Administration of AP, USFDA, KFDA, PMDA, KFDA and WHO GMP



  • FINISHED DOSAGE FORMS MANUFACTURING AT NACHARAM

    Expansive manufacturing unit spread across 5000 m2 exclusively for solid dosage forms, with special emphasis on modified-release formulations. The facility is inspected and approved by USFDA and MoH – Iran.



  • CLINICAL RESEARCH AND BIOSCIENCES AT BALANAGAR

    State-of-the-art, modern facility containing 114 beds and 5 LC-MS/MS and approved by major regulatory authorities including USFDA, EU (Project based), MoH – Turkey, BPFK – Malaysia and UAE MoH.



  • API MANUFACTURING AT JAGGAIAHPET

    Custom built API manufacturing site equipped with the latest technology, with a capacity of 210 KL and 7 clean rooms. The facility is inspected and approved by the Drug Control Administration of AP, USFDA, KFDA, PMDA, KFDA and WHO GMP



  • FINISHED DOSAGE FORMS MANUFACTURING AT NACHARAM

    Expansive manufacturing unit spread across 5000 m2 exclusively for solid dosage forms, with special emphasis on modified-release formulations. The facility is inspected and approved by USFDA and MoH – Iran.



  • CLINICAL RESEARCH AND BIOSCIENCES AT BALANAGAR

    State-of-the-art, modern facility containing 114 beds and 5 LC-MS/MS and approved by major regulatory authorities including USFDA, EU (Project based), MoH – Turkey, BPFK – Malaysia and UAE MoH.



  • API MANUFACTURING AT JAGGAIAHPET

    Custom built API manufacturing site equipped with the latest technology, with a capacity of 210 KL and 7 clean rooms. The facility is inspected and approved by the Drug Control Administration of AP, USFDA, KFDA, PMDA, KFDA and WHO GMP



  • FINISHED DOSAGE FORMS MANUFACTURING AT NACHARAM

    Expansive manufacturing unit spread across 5000 m2 exclusively for solid dosage forms, with special emphasis on modified-release formulations. The facility is inspected and approved by USFDA and MoH – Iran.



  • CLINICAL RESEARCH AND BIOSCIENCES AT BALANAGAR

    State-of-the-art, modern facility containing 114 beds and 5 LC-MS/MS and approved by major regulatory authorities including USFDA, EU (Project based), MoH – Turkey, BPFK – Malaysia and UAE MoH.



  • API MANUFACTURING AT JAGGAIAHPET

    Custom built API manufacturing site equipped with the latest technology, with a capacity of 210 KL and 7 clean rooms. The facility is inspected and approved by the Drug Control Administration of AP, USFDA, KFDA, PMDA, KFDA and WHO GMP



  • FINISHED DOSAGE FORMS MANUFACTURING AT NACHARAM

    Expansive manufacturing unit spread across 5000 m2 exclusively for solid dosage forms, with special emphasis on modified-release formulations. The facility is inspected and approved by USFDA and MoH – Iran.



  • CLINICAL RESEARCH AND BIOSCIENCES AT BALANAGAR

    State-of-the-art, modern facility containing 114 beds and 5 LC-MS/MS and approved by major regulatory authorities including USFDA, EU (Project based), MoH – Turkey, BPFK – Malaysia and UAE MoH.



  • API MANUFACTURING AT JAGGAIAHPET

    Custom built API manufacturing site equipped with the latest technology, with a capacity of 210 KL and 7 clean rooms. The facility is inspected and approved by the Drug Control Administration of AP, USFDA, KFDA, PMDA, KFDA and WHO GMP



  • FINISHED DOSAGE FORMS MANUFACTURING AT NACHARAM

    Expansive manufacturing unit spread across 5000 m2 exclusively for solid dosage forms, with special emphasis on modified-release formulations. The facility is inspected and approved by USFDA and MoH – Iran.



  • CLINICAL RESEARCH AND BIOSCIENCES AT BALANAGAR

    State-of-the-art, modern facility containing 114 beds and 5 LC-MS/MS and approved by major regulatory authorities including USFDA, EU (Project based), MoH – Turkey, BPFK – Malaysia and UAE MoH.



  • API MANUFACTURING AT JAGGAIAHPET

    Custom built API manufacturing site equipped with the latest technology, with a capacity of 210 KL and 7 clean rooms. The facility is inspected and approved by the Drug Control Administration of AP, USFDA, KFDA, PMDA, KFDA and WHO GMP



  • FINISHED DOSAGE FORMS MANUFACTURING AT NACHARAM

    Expansive manufacturing unit spread across 5000 m2 exclusively for solid dosage forms, with special emphasis on modified-release formulations. The facility is inspected and approved by USFDA and MoH – Iran.



  • CLINICAL RESEARCH AND BIOSCIENCES AT BALANAGAR

    State-of-the-art, modern facility containing 114 beds and 5 LC-MS/MS and approved by major regulatory authorities including USFDA, EU (Project based), MoH – Turkey, BPFK – Malaysia and UAE MoH.



  • API MANUFACTURING AT JAGGAIAHPET

    Custom built API manufacturing site equipped with the latest technology, with a capacity of 210 KL and 7 clean rooms. The facility is inspected and approved by the Drug Control Administration of AP, USFDA, KFDA, PMDA, KFDA and WHO GMP



  • FINISHED DOSAGE FORMS MANUFACTURING AT NACHARAM

    Expansive manufacturing unit spread across 5000 m2 exclusively for solid dosage forms, with special emphasis on modified-release formulations. The facility is inspected and approved by USFDA and MoH – Iran.



  • CLINICAL RESEARCH AND BIOSCIENCES AT BALANAGAR

    State-of-the-art, modern facility containing 114 beds and 5 LC-MS/MS and approved by major regulatory authorities including USFDA, EU (Project based), MoH – Turkey, BPFK – Malaysia and UAE MoH.



  • API MANUFACTURING AT JAGGAIAHPET

    Custom built API manufacturing site equipped with the latest technology, with a capacity of 210 KL and 7 clean rooms. The facility is inspected and approved by the Drug Control Administration of AP, USFDA, KFDA, PMDA, KFDA and WHO GMP



  • FINISHED DOSAGE FORMS MANUFACTURING AT NACHARAM

    Expansive manufacturing unit spread across 5000 m2 exclusively for solid dosage forms, with special emphasis on modified-release formulations. The facility is inspected and approved by USFDA and MoH – Iran.



  • CLINICAL RESEARCH AND BIOSCIENCES AT BALANAGAR

    State-of-the-art, modern facility containing 114 beds and 5 LC-MS/MS and approved by major regulatory authorities including USFDA, EU (Project based), MoH – Turkey, BPFK – Malaysia and UAE MoH.



  • API MANUFACTURING AT JAGGAIAHPET

    Custom built API manufacturing site equipped with the latest technology, with a capacity of 210 KL and 7 clean rooms. The facility is inspected and approved by the Drug Control Administration of AP, USFDA, KFDA, PMDA, KFDA and WHO GMP



  • FINISHED DOSAGE FORMS MANUFACTURING AT NACHARAM

    Expansive manufacturing unit spread across 5000 m2 exclusively for solid dosage forms, with special emphasis on modified-release formulations. The facility is inspected and approved by USFDA and MoH – Iran.



  • CLINICAL RESEARCH AND BIOSCIENCES AT BALANAGAR

    State-of-the-art, modern facility containing 114 beds and 5 LC-MS/MS and approved by major regulatory authorities including USFDA, EU (Project based), MoH – Turkey, BPFK – Malaysia and UAE MoH.



  • API MANUFACTURING AT JAGGAIAHPET

    Custom built API manufacturing site equipped with the latest technology, with a capacity of 210 KL and 7 clean rooms. The facility is inspected and approved by the Drug Control Administration of AP, USFDA, KFDA, PMDA, KFDA and WHO GMP



  • FINISHED DOSAGE FORMS MANUFACTURING AT NACHARAM

    Expansive manufacturing unit spread across 5000 m2 exclusively for solid dosage forms, with special emphasis on modified-release formulations. The facility is inspected and approved by USFDA and MoH – Iran.



  • CLINICAL RESEARCH AND BIOSCIENCES AT BALANAGAR

    State-of-the-art, modern facility containing 114 beds and 5 LC-MS/MS and approved by major regulatory authorities including USFDA, EU (Project based), MoH – Turkey, BPFK – Malaysia and UAE MoH.



  • API MANUFACTURING AT JAGGAIAHPET

    Custom built API manufacturing site equipped with the latest technology, with a capacity of 210 KL and 7 clean rooms. The facility is inspected and approved by the Drug Control Administration of AP, USFDA, KFDA, PMDA, KFDA and WHO GMP



  • FINISHED DOSAGE FORMS MANUFACTURING AT NACHARAM

    Expansive manufacturing unit spread across 5000 m2 exclusively for solid dosage forms, with special emphasis on modified-release formulations. The facility is inspected and approved by USFDA and MoH – Iran.



  • CLINICAL RESEARCH AND BIOSCIENCES AT BALANAGAR

    State-of-the-art, modern facility containing 114 beds and 5 LC-MS/MS and approved by major regulatory authorities including USFDA, EU (Project based), MoH – Turkey, BPFK – Malaysia and UAE MoH.


our Profile

RA Chem Pharma Limited is a vertically integrated pharmaceutical company.Over the past 10 years, it has expanded
its spectrum by establishing state-of-the-art manufacturing facilities in API, Formulations and Clinical Research.


RA GROUP CONSISTS OF

cGMP compliant API manufacturing facility located in Jaggayapet, Krishna District

cGMP compliant solid dosage formulation manufacturing facility at Nacharam,


Read more!

Board of Directors

Mr.R. Sirish Kumar
Managing Director

He qualified with a dual degree in Chemistry

Readmore

Mr.Divyang Kapadia
Independent Director

Qualification: Chartered Accountant and Cost

Readmore

Mr.P.S. Rao
Independent Director

He is an Organic Chemist with PG Diploma in Business

Readmore

Mr.VIJAYA KRISHNA
Director

Over 34 years of post qualification experience

Readmore

Mile Stones

2003

Acquired API facility at Jaggaiahpet



2004

Upgraded the API facility to GMP standards


2005

. API facility was made FDA compliant
. Entered Formulation Business

2006

.Started Clinical Research and Biosciences
.Acquired formulation at Balanagar

2007

USFDA approval for API plant



2008

Obtained MHRA approval for CRBio (Project-based)


2009

.MOH Turkey approval for CRBio
.Japanese approval for API

2010

Expansion of API facility



2011

Expansion of CRBio facility



Readmore!

Vision and Mission

“Our vision is to be a leading pharmaceutical company in India and to become a significant global player by providing high quality, affordable and innovative solutions in medicine and treatment."


Philosophy

RA Chem Pharma was built with a focused, long-term philosophy


Total Quality:

Unwavering commitment to quality in all aspects – from building state-of-the-art facilities and technology, to employees being trained to maintain highest quality and regulatory standards.



Readmore!

Quality Policy



We at RA Chem Pharma Ltdare committed towards a common goal of total customer satisfaction and confidence by providing end to end services to all the clients by continually improving Quality Management System in accordance with cGMP, other regulatory and statutory guidelines.


We shall strive to become globally respected partner driven by strong research & technical capabilities with emphasis on intellectual property and confidentiality.


We as a cohesive & dynamic team shall strive to exceed stakeholders expectations by focusing on customer requirements, empowering employees and maximizing organizational profitability &shareholder wealth.


RACHEM Products

  • API

  • Commercial Products, Manufactured under Exclusivity, New Products for Commercial Launch

    Readmore...

  • API Intermediates

  • Lamotrigine, Midazolam, Tamsulosin, Fexofenadine, Entacapone, Donepezil,Pranlukast

    Readmore...

  • Formulations

  • Commercialized, Scale up, Development Pipeline, SUSPENSIONS

    Readmore...

  • Pre-Formulations Intermediates

  • Commericialized, Underdevelpment

    Readmore...

CAPABILITIES

Prodcuts

Contact Us

  •   Plot No: 26 & 27, Techno Industrial Estate, Balanagar, Hyd - 500037 Telangana, India
  •  +91-40-44758595
  •  +91-40-44758596
  • info@rachempharma.com
Copyright © 2017 RAChem. All rights reserved.